{"protocolSection":{"identificationModule":{"nctId":"NCT05324371","orgStudyIdInfo":{"id":"S2423"},"organization":{"fullName":"Boston Scientific Corporation","class":"INDUSTRY"},"briefTitle":"A Pilot Study to Assess WATCHMAN FLX™ Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography: WATCHMAN FLX™ CT","officialTitle":"A Pilot Study to Assess WATCHMAN FLX™ Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography: WATCHMAN FLX™ CT"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-03-17","studyFirstSubmitQcDate":"2022-04-11","studyFirstPostDateStruct":{"date":"2022-04-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-20","lastUpdatePostDateStruct":{"date":"2024-01-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boston Scientific Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the risk of stroke. Serial advanced imaging modalities such as CT and TEE will be used."},"conditionsModule":{"conditions":["The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":25,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Device Arm","type":"EXPERIMENTAL","description":"WATCHMAN FLX™ device implantation","interventionNames":["Device: Watchman FLX Device"]}],"interventions":[{"type":"DEVICE","name":"Watchman FLX Device","description":"Left atrial appendage closure using the Watchman FLX device","armGroupLabels":["Device Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Device tissue coverage","description":"• Device surface morphology (inclusive of tissue coverage) post implant procedure as assessed over time using the serial advanced imaging modalities of cardiac computed tomography (CT) and transesophageal echocardiography (TEE)","timeFrame":"14, 45 and 90 days post-implant"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is of legal age to participate in the study per the laws of their respective geography.\n* Subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve).\n* Subject is clinically indicated for a WATCHMAN FLX device.\n* Subject is deemed suitable for the protocol-defined pharmacologic regimen.\n* Subject or legal representative is able to understand and willing to provide written informed consent to participate in the study.\n* Subject is able and willing to return for required follow-up visits and examinations.\n\nExclusion Criteria:\n\n* Subject is currently enrolled in another investigational study, except if the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatment.\n* Subject has eGFR \\<30 mL/min (chronic kidney disease stage IV or stage V).\n* Subject is contraindicated for TEE.\n* Subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction (e.g., due to an underlying hypercoagulable state).\n* Subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to, cardioversion, percutaneous coronary intervention, cardiac ablation, cataract surgery, etc.).\n* Subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment.\n* Subject had a prior major bleeding event per ISTH definitions within the 30 days prior to enrollment. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source are a further exclusion regardless of timing of the bleeding event.\n* Subject has an active bleed.\n* Subject has a reversible cause for AF or has transient AF.\n* Subject has no LAA or the LAA is surgically ligated.\n* Subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment.\n* Subject has a history of atrial septal repair or has an atrial septal defect/patent foramen ovale (ASD/PFO) device.\n* Subject has a known contraindication to percutaneous catheterization procedure.\n* Subject has a cardiac tumor.\n* Subject has signs/symptoms of acute or chronic pericarditis.\n* Subject has an active infection.\n* There is evidence of tamponade physiology.\n* Subject has New York Heart Association Class IV congestive heart failure at the time of enrollment.\n* Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment per study physician's discretion).\n* Subject has a documented life expectancy of less than 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Nilou Zilinek","role":"CONTACT","phone":"508-683-6127","email":"Nilou.Zilinek@bsci.com"}],"overallOfficials":[{"name":"Jens Erik Nielsen-Kudsk, MD","affiliation":"Aarhus University Hospital Skejby","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Aarhus University Hospital","status":"RECRUITING","city":"Aarhus","country":"Denmark","contacts":[{"name":"Jens Erik Nielsen-Kudsk, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":56.15674,"lon":10.21076}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED","description":"The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}